More on Immunomedics (IMMU): FQ4 misses across the board. Revenue was down Y/Y, due primarily to...

|By:, SA News Editor

More on Immunomedics (IMMU): FQ4 misses across the board. Revenue was down Y/Y, due primarily to the milestone payment received during the prior year period. Bottom line numbers also suffered from higher than anticipated R&D spending, particularly on further clinical development of its pancreatic cancer drug clivatuzumab.